About: Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Latest price: $13.55 (-1.02%)
SLNNASDAQSilence Therapeutics PLC
Silence Therapeutics PLC share price
SLN price activity
Last Price
$13.550
Change (24hr)
-0.14 USD (-1.02%)
Volume
644.72K
Volume (4w avg)
-
Open
$13.60
Day Range
$13.36 - $14.00
Previous Close
$13.69
Last Trade
09 Sep, 8:00 pm GMT+0
Delayed
09 Sep, 8:00 pm GMT+0
SLN price performance
Delayed
09 Sep, 8:00 pm GMT+0
SLN Market Signals